Viatris Misses Estimates, Cash Flow Up

(NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt reduction and strategic advancements, Viatris fell short of analysts' forecasts. The adjusted earnings per share (EPS) stood at $0.54, missing the estimated $0.56, while total revenue reached $3,528 million, trailing the predicted $3,592 million.

Although its internal targets were achieved, the external market expectations were not met, reflecting a quarter with both strategic progress and financial challenges.

Source: Analyst estimates for the quarter provided by FactSet.

Source Fool.com